Why Revolution Medicines, Inc. (RVMD) stock moved
Revolution Medicines, Inc. (RVMD) shares rose 4.8% to $199.86 as of September 25, 2026, a moderate gain from the prior close of $190.74. BestStocks flagged the session as a major change for RVMD. The move is tied to price move up. Below, we break down what changed for RVMD, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RVMD climbed 4.8% to $199.86
RVMD rose 4.8% in its latest session, moving from $190.74 to $199.86.
What it means for Revolution Medicines, Inc. investors
For Revolution Medicines, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.8% session move. Weighing against that: Revolution Medicines shares fell 4.18% to $196.30, driven by a combination of profit-taking following the FDA's recent Breakthrough Therapy Designation for pancreatic cancer drug Rasonque, plus insider selling pressure; Revolution Medicines, Inc. (RVMD) moved -3.10% from $186.16 to $180.39 on 2026-07-20. Wall Street's consensus price target sits at $248.25, implying +24.2% upside from $199.86. BestStocks rates the overall signal quality medium (63/100). With earnings roughly 40 days out, the next report is the most likely near-term test of the move.
RVMD price reaction
RVMD last traded at $199.86, up $9.12 (+4.78%) from the previous close of $190.74. The session traded on 1.7× average volume (above avg), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Revolution Medicines, Inc. (RVMD)
The consensus analyst price target on Revolution Medicines, Inc. (RVMD) is $248.25, 24.2% above the recent $199.86. Over the past 90 days analysts logged 0 upgrades, 26 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RVMD line up.
The bullish case
- Wall Street's consensus price target of $248.25 implies +24.2% upside from $199.86.
- The Street's most bullish target is $320.00 (+60.1%).
- Material positive event.
- Positive 4.8% session move.
- Revolution Medicines, Inc. (RVMD) moved +3.90% from $179.18 to $186.16 on 2026-07-17.
The bearish case
- The most bearish analyst target is $179.00 (-10.4%).
- Revolution Medicines shares fell 4.18% to $196.30, driven by a combination of profit-taking following the FDA's recent Breakthrough Therapy Designation for pancreatic cancer drug Rasonque, plus insider selling pressure.
- Revolution Medicines, Inc. (RVMD) moved -3.10% from $186.16 to $180.39 on 2026-07-20.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 25, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RVMD
Frequently asked questions about RVMD
Why did Revolution Medicines, Inc. (RVMD) stock move?
RVMD rose 4.8% to $199.86. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RVMD stock rise?
RVMD gained 4.78% ($9.12) versus the prior close of $190.74, last trading at $199.86 on 1.7× average volume.
When is Revolution Medicines, Inc.'s next earnings date?
RVMD's next earnings report is estimated for 2026-11-04 — about 40 days away.
What is the analyst price target for RVMD?
The consensus analyst price target for RVMD is $248.25, about 24.2% above the current $199.86. Over the past 90 days, analysts recorded 0 upgrades, 26 maintains, and 0 downgrades.
How BestStocks tracks RVMD
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for RVMD, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 25, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.